AZM treatment resulted in an increased percentage of CD209+ M2 macrophages in CF macrophages (Figure 4A,B), and an enhanced release of CCL18 in both HC and CF M2 macrophages (Figure 4C). This evidence concerns the gene CCL18 and cystic fibrosis.